Law360 (February 14, 2020, 7:09 PM EST) -- A Pennsylvania federal judge ruled Friday that investors in a would-be class action against Endo International PLC had failed to bring forward sufficient evidence to support their claim that the pharmaceutical company conspired with competitors to fix prices for generic drugs.
While U.S. District Judge Michael Baylson said that Endo had admitted it raised prices in near lockstep with competitors, he ruled that such practices were not, in and of themselves, enough to prove that the company was affirmatively engaged in an antitrust conspiracy.
"Defendants have disclosed they followed a practice of what is called 'parallel pricing,' but parallel pricing ipso...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!